Dr Jim Freeth | Managing Director

Dr Jim Freeth, Managing Director, Retrogenix

Jim is Managing Director of Retrogenix, having co-founded the company in 2008. This followed 10+ years in management within the biotechnology (Oxford BioMedica) and pharmaceutical industry (AstraZeneca). He is a biologist by training, and obtained his PhD at Manchester University, UK, in 1997.


EAC 2017 Day 1, Tuesday 31st October 2017 @ 11:35

Plenary Roundtable Discussion Session

9 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.

TABLE 3 Assessing target specificity of biotherapeutics

EAC 2017 Day 1, Tuesday 31st October 2017 @ 15:10

Uncovering critical receptors and safety screening for target specificity using human cell microarray technology

  • A powerful approach to identify specific receptors for phenotypic antibodies and immune  checkpoint ligands
  • Efficient off-target profiling of biotherapeutics including antibodies, ADCs, scFvs and whole CAR T cells

back to speakers